Southern Thoracic Surgical Association CABG in 2012: Implications of the New ESC/EACTS Guidelines
|
|
- Patience Watkins
- 5 years ago
- Views:
Transcription
1 Southern Thoracic Surgical Association 2011 CABG in 2012: Implications of the New ESC/EACTS Guidelines David P Taggart MD PhD FRCS Professor of Cardiovascular Surgery, University of Oxford Conflicts of Interest: (i) Clinical: Cardiac Surgeon (ii) Political: President SCTS GB and Ireland; Chair ESC Working Group Cardiovascular Surgery (iii) Commercial: Consultant to Medtronic, Abbott, AstraZeneca, Novadaq, VGS, (iv) One of 25 ESC/EACTS Guidelines Writers on Myocardial Revascularization
2 Joint ESC/EACTS Guidelines for Myocardial Revascularization 2010 Table 9. Indications for CABG versus PCI in stable patients with lesions suitable for both procedures and low predicted surgical mortality 79% 65% In the most severe patterns of CAD, CABG appears to offer a survival advantage as well as a marked reduction in the need for repeat revascularisation. ACC/AHA guidelines for PCI 08/11/2011 very similar recommendations
3 Results of contemporary CABG are excellent!!! o3102 patients randomized to single or bilateral IMA grafts primary outcome is 10 year survival 67 surgeons, 28 centres, seven countries 30 day mortality 1.2%, 1 yr mortality 2.4% 1 year incidence of stroke, MI, repeat revascularization all < 2%
4 Ann Thorac Surg 2006;82: patients in total Only enrolled 5% of total potentially eligible population 65% had 1 or 2 VD all with normal LV function only 40% had proximal LAD disease only 79% received an IMA ie Trials failed to show a survival benefit of CABG over PCI as they only included patients in whom it could be predicted that there was NO prognostic benefit from any revascularization
5 Evidence Basis for an Intervention (CABG vs PCI) Strengths Potential Weaknesses RCT The Gold standard No Bias Small numbers of patients Small % of eligible population Atypical patient populations Short duration of follow-up Large numbers of cross-overs (19/20 RCT of CABG vs PCI) Registries (Propensity Matched) Large Numbers of Patients (often tens of thousands) Represent real clinical practice (1/20 RCT of CABG vs PCI) Confounding/Bias
6 3VD (No Left Main)
7 1. EVIDENCE FROM RCT of PCI vs CABG (Pre-SYNTAX) Hlatky [Lancet 2009] Studies 10 RCT CABG vs PCI Patients 7812 Median Follow-up 6 years HR for death with CABG 0.91 (p=0.12) HR for death with PCI - Death/Repeat Revasc 10% vs 25% (p=0.001) HR Death CABG in Diabetics 0.7 (p=0.014) HR Death CABG >65 yrs 0.82 (p=0.002) Jeremias [Am J Med 2009] 28 RCT CABG or PCI vs OMT years 0.62 ( ) 0.82 ( ) - - -
8 2. EVIDENCE FROM REGISTRIES of PCI vs CABG (Pre-SYNTAX) NEJM 2005 onew York Registry: 37,212 CABG and 22,102 PCI (BMS) patients with > 2VD Propensity matched for cardiac and non-cardiac co-morbidity risk Absolute Survival Benefit of 5% with CABG at 3 years Reintervention at 3 years: 35% of PCI vs 5% CABG 31% risk of death ocabg: Survival + freedom from revasc INCREASE WITH TIME!! PCI/CABG studies with <3 years follow up are only interim analyses
9 CABG Has Survival Benefit Over PCI in Real Life Clinical Practice Author Year Patients DM Stents Follow- Up CABG vs PCI Hannan NEJM ,400p - DES 1.5 yrs HR 0.8 (p=0.03) Bair CIRC ,369 - DES 5 yrs HR 0.85 (p<0.001) Javaid CIRC ,680 - DES 1 yr 97% vs 89% Hannan NEJM ,314p - BMS 3 yrs mortality 5% Malenka CIRC ,493 - BMS 7 yrs HR 0.6 (p <0.01) BARI JACC yrs 58% vs 46% Javaid CIRC DES 1 yr 3% vs 12-18% Niles JACC , yrs HR SUMMARY 102, yrs mortality oin (>100,00) REAL-LIFE patients with 3VD, by 3-5 years CABG increases ABSOLUTE survival by around 5% vs PCI CABG decreases ABSOLUTE reintervention x5 vs PCI IMPORTANT WARNING FOR SYNTAX TRIAL!!
10 7235 patient pairs propensity matched for 32 factors with 8 yr FU PCI CABG CABG HR numbers All Deaths 29% 22% 0.68 ( ) <0.001 LAD DISEASE nos PCI death CABG death CABG HR 3 VD Proximal % 22% 0.68 ( ) < VD Non Proximal % 22% 0.53 ( ) < VD Proximal % 21% 0.78 ( ) < VD Non Proximal % 23% 0.70 ( ) < VD None % 25% 0.78 ( ) <0.05 DES have not been shown to have survival benefit over BMS
11 Taggart DP. Lancet 2009; 373: Most significantly, the randomized trials only enrolled around 5%-10% of the eligible population, the majority of whom had single or double vessel disease and normal left ventricular function [2], a group in whom it was already well established that there was no prognostic benefit of CABG [3]. By largely excluding patients with a known survival benefit from CABG (left main+/- triple vessel coronary artery disease and especially with impaired ventricular function [3]), the trials ignored the prognostic benefit of surgery in more complex coronary artery disease. Nevertheless, the inappropriate generalization of the trial results from their highly select populations to most patients with multivessel disease has been ubiquitous in the literature and has, at least in part, justified the explosive growth in PCI in developed countries. [2] Taggart DP. Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann Thorac Surg 2006;82: [3] Yusuf S, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994 ;344:
12 THE SYNTAX TRIAL Landmark trial (most important trial ever of PCI vs CABG) odesigned to look at 5 year outcomes death and MACCE o All comer trial (vs highly select patients in all previous RCTs) oparallel Registry (35% of patients straight to CABG!!)
13 SYNTAX RCT Results (4/5 Years): 3 Vessel Disease PCI CABG nos Death Cardiac Death MI <.001 CVA D+C+M Revasc <.001 Consistent with PPM registry data Similar rate of stroke in PCI/CABG Low <23 Intd High >32 nos death CVA MI D+C+M Revasc nos death CVA MI D+C+M Revasc nos death CVA MI D+C+M Revasc
14 Fundamental Question WHY DOES CABG HAVE SUCH A SURVIVAL BENEFIT OVER PCI? Anatomically, atheroma is mainly located in the proximal coronary arteries During CABG placing bypass grafts to the MID CORONARY VESSEL has TWO effects (i) treats the CULPRIT lesion (of ANY complexity) (ii) over the long term, CABG offers prophylaxis against FUTURE culprit lesions by protecting whole zones of vulnerable proximal myocardium in diffusely unstable coronary endothelium In contrast, PCI with stents ( ) only treats SUITABLE localised proximal culprit lesions but has NO PROPHYLACTIC BENEFIT against new disease (proximal to, within or distal to the stent) which nullifies the benefit of the stent 2. PCI means incomplete revascularization (Hannan Circ 2006) Of 22,000 PCI 69% had incomplete revascularization >2 vessels (+/- CTO) HR for mortality 1.4 (95% CI = ) PCI will never match the results of CABG for LM/MVD (POBA;BMS;DES)
15 Left main (+/- 1,2,3 vcad)
16 o<90% of LMS are distal/bifurcation (very high risk of restenosis) o<90% have multivessel CAD (CABG already offers survival benefit)
17 SYNTAX RCT Results (4/5 Years): Left Main: n=705 PCI CABG nos Death *.94 Cardiac Death *.26 MI CVA *.03 D+C+M Revasc * = different from 3VD EXCEL TRIAL (Abbott Vascular) 2600 patient RCT: PCI vs CABG only in SYNTAX Score < registry patients ie 3600 in total started Sept 2010 Low <23 Intd High >32 nos death CVA MI D+C+M Revasc nos death CVA MI D+C+M Revasc nos death CVA MI D+C+M Revasc <001
18 o PRECOMBAT : 600 patient RCT (300 PCI vs 300 CABG) Cohort of 1454 LM patients (59% NOT randomized) Mean SYNTAX score: 25 (vs 30 in SYNTAX) Mean Euroscore: 2.7 (vs 3.8 in SYNTAX) Primary endpoint: Death; CVA; MI; Repeat Revasc Primary Endpoint Primary Endpoint (-Revasc) oincidence of stroke 0.4% PCI vs 0.7% CABG ono increase in mortality or stroke with CABG c/w SYNTAX
19 ojoint Cardiology (ESC) and Cardiac Surgery (EACTS) o25 members from 13 European countries 9 non interventional cardiologists, 8 interventional cardiologists, 8 cardiac surgeons Reflects the Heart Team!!! oextensively reviewed by external referees before publication
20 Class of Recommendation and Level of Evidence Class of Recommendation I II III IIa IIb Evidence and /or general agreement that treatment or procedure is beneficial, useful, effective Conflicting evidence and/or opinion about usefulness/efficacy Weight of evidence in favour Evidence/opinion less well established Evidence or general agreement that treatment/procedure is NOT useful/effective and in some cases may be dangerous Means Do it Consider it Should consider Could consider Do NOT do it Level of Evidence A B C Data from multiple RCT or meta-analyses Single RCT or large non-randomized studies Consensus of expert opinions and/or small studies/ retrospective studies/ registries
21 Joint ESC/EACTS Guidelines for Myocardial Revascularization 2010 Table 9. Indications for CABG versus PCI in stable patients with lesions suitable for both procedures and low predicted surgical mortality 79% 65% In the most severe patterns of CAD, CABG appears to offer a survival advantage as well as a marked reduction in the need for repeat revascularisation. By Aug 2011 endorsed by 29 European Societies of Cardiology and 4 CT Surgery
22 14 chapters 270 references
23 Do we really need guidelines and multidisciplinary teams? Joint ESC/EACTS Guidelines for Myocardial Revascularization 2010 Adherence of Catheterization Laboratory Cardiologists to ACC/AHA Guidelines for PCI and CABG: What happens in Actual Practice? [Hannan et al Circ 2010] o16142 catheter lab patients in New York otreatment decision made by catheter lab cardiologist alone in 64% ACC/AHA Recommendation Numbers % CABG % PCI % Medical None CABG PCI <1 CABG or PCI <1 Neither Total <1 o92% of PCI procedures ad hoc (ie no time for real choice/ genuine consent) ochance of PCI increased in hospitals with PCI facilities
24 10 studies of 1458 patients (1016 PCI; 442 CABG) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Improve Angina X X X Extend Life Prevent MI Offered Alternative owidespread misunderstanding of rationale for PCI ono surgical opinion in 85%!!! oneed for Guideline/MDT approach to recommend intervention CAB G
25 onational Cardiovascular Data Registry 01/07/09-30/09/10 o1091 US hospitals o PCIs o71% Acute: 98.6% Appropriate; 0.3% uncertain; 1.1% Inappropriate o29% NonAcute: 50% Appropriate; 38% uncertain; 12% Inappropriate Inappropriate: No angina 54%; No ischaemia 72%; Suboptimal medication 96% Inappropriate: Median 11% (IQ 6%-17%); Range 0-55%
26 Joint ESC/EACTS Guidelines for Myocardial Revascularization Patient Information Patient information needs to be objective and unbiased, patient orientated, evidence based, up-to-date, reliable, understandable, accessible, relevant and consistent with legal requirements. Informed consent requires transparency, especially if there is controversy about the indication for a particular intervention. Specialty bias and self referral should not interfere with the process. For patients with stable CAD and multivessel or LM disease all relevant data should be reviewed by a non-invasive cardiologist, a cardiac surgeon and an interventional cardiologist (Heart Team) to determine the likelihood of safe and effective revascularization with either PCI or CABG. Myocardial revascularization should in general not be performed at the time of diagnostic angiography, thereby allowing the Heart team sufficient time, to assess all available information, reach a consensus and clearly explain and discuss the findings with the patient. Standard evidence-based interdisciplinary institutional protocols may be used for common case scenarios, but complex cases should be discussed individually to find the best solution. 4.2 Multidisciplinary decision making (Heart Team) The creation of a Heart Team serves the purpose of a balanced multidisciplinary decision process. Standard protocols compatible with the current Guidelines may be used to avoid the systematic need for case-by-case review of all diagnostic angiograms. Ad Hoc percutaneous coronary intervention With the exception of unstable patients or candidates for ad hoc PCI (Table 4), the patient should be offered enough time, up to several days as required, between diagnostic catheterization and intervention, to reflect Ad hoc PCI is therefore reasonable for many patients, but not desirable for all, and should not automatically be applied as a default approach. Institutional protocols defined by the Heart Team should be used to define specific anatomical criteria and clinical subsets that can or cannot be treated by ad hoc PCI.
27 Summary and Conclusions: CABG vs PCI in 2012 o79% of ALL 3VD (SYNTAX>22) and 65% ALL LM (SYNTAX >32) CABG has superior survival, freedom from MI and repeat revasc at 3yrs Consistent with registry evidence in the literature CABG has same risk of CVA as PCI for 3VD but 4.0% vs 1.2% for LM PCI may be best treatment for ostial/mid shaft LM (EXCEL trial) PCI has an important role in patients unfit for or who refuse CABG o Strong evidence that most PCI patients misunderstand its rationale MDTs/Heart Team must ensure patients receive appropriate information If intervention follows guideline recommendations no need for MDT Ad hoc PCI denies real patient choice and genuine informed consent o Results of contemporary CABG are excellent but could be even better More use of arterial grafts (especially 2 nd IMA) More off pump CABG in higher risk patients Confirmation of graft patency in operating room
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationSAHA PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG
SAHA 2017 PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG David P Taggart MD PhD FRCS FESC Professor of Cardiovascular Surgery,
More informationCABG vs PCI: What do the Guidelines Say?
AATS International Cardiovascular Symposium: Sao Paolo 2017 CABG vs PCI: What do the Guidelines Say? David P Taggart MD PhD FRCS FESC Professor of Cardiovascular Surgery, University of Oxford Conflicts
More informationWhat do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
More informationImplications of SYNTAX for CABG in 2010: Practice and Politics
AATS 2010 Implications of SYNTAX for CABG in 2010: Practice and Politics David P Taggart MD PhD FRCS Professor Cardiovascular Surgery, University of Oxford Conflicts of Interest: (i) Clinical: Cardiac
More informationTCTAP When is Surgery the Preferred Therapy? David P Taggart MD PhD FRCS Professor Cardiovascular Surgery, University of Oxford
TCTAP 2010 When is Surgery the Preferred Therapy? David P Taggart MD PhD FRCS Professor Cardiovascular Surgery, University of Oxford Conflicts of Interest: (i) Clinical: Cardiac Surgeon (ii) Political:
More informationManagement of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationMultivessel Coronary Artery Disease : CABG. Zürich, F. Siclari MD
Multivessel Coronary Artery Disease : CABG Zürich, 10.06.2015 F. Siclari MD Coronary Artery Ruptured Plaque Pathological process with definite subsequent vascular changes most of them irreversible CABG
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationAssessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationLe# Main Interven-on: When Is It Appropriate. Femi Philip, MD Assistant Professor Of Medicine UC Davis
Le# Main Interven-on: When Is It Appropriate Femi Philip, MD Assistant Professor Of Medicine UC Davis Nil Disclosures Outline What is the LMCA? Should we revascularize severe LMCA disease? What revascularizacon
More informationReconciling the Results of the Randomized Trials
Management of Stable Angina in Multivessel Disease: Reconciling the Results of the Randomized Trials Eric A. Cohen MD, FRCPC Schulich Heart Centre Sunnybrook Health Sciences Centre Toronto ON ACC Rockies
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationChronic Total Occlusion: a case for coronary artery bypass grafting
Chronic Total Occlusion: a case for coronary artery bypass grafting Rune Haaverstad Professor & Chief Dept. of Cardiothoracic Surgery Haukeland University Hospital Bergen, Norway Disclosure Research cooperation
More informationAdecade ago, many cardiac surgeons believed
CABG for Multivessel CAD Recent studies show that CABG is still preferred over PCI for most patients. BY SUBHASIS CHATTERJEE, MD; JOHN C. ALEXANDER, MD; AND PAUL J. PEARSON, MD, PHD Adecade ago, many cardiac
More informationLeft Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationAbbott Vascular. PROTOCOL EXCEL Clinical Trial
Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left
More informationUpdate 2012 Herzchirurgie
Update 2012 Herzchirurgie Prof. Dr. Jürg Grünenfelder Klinik für Herz- und Gefässchirurgie UniversitätsSpital Zürich Themenübersicht - update Koronarchirurgie - Syntax 5 Jahre - Freedom 5 Jahre - update
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More informationSYNTAX score before decision making! Corrado Tamburino, MD, PhD
SYNTAX score in left main - Tamburino TCT Asia Pacific Seoul, 27 April 2011 Slide 1 SYNTAX score before decision making! Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate
More informationThe Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study Five-Year Results in the French Subset René Koning, MD On behalf of the SYNTAX investigators Three-year
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationMost Patients with Elective Left Main Disease. Farrel Hellig
Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationRevascularization In HFrEF: Are We Close To The Truth. Ali Almasood
Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationFFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium
FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationCOMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationAdvances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline
Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationTrial. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Trial International Study of Comparative Health Effectiveness with Medical and Invasive Approaches Stable Ischemic Heart Disease What is the best initial management strategy for patients with SIHD? What
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationClinical Considerations for CTO
38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research
More informationGuidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI
Guidelines/Appropriateness ARCH 2015 St Louis, Missouri April 9-11, 2015 Manish A. Parikh, MD, FACC,FSCAI Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian
More informationR&M Solutions
PCI with DES versus CABG & syntax score Dr. Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology, Alexandria University, Egypt Head of Cardiology Department President of Egyptian Society of Cardiology
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More informationMedical Rx vs PCI vs CABG
Medical Rx vs PCI vs CABG S. Hinan Ahmed, MD Associate Professor: Cardiology and Cardiothoracic Surgery Program Director: Interventional Fellowship Program Assoc Editor: Cath and Cardiovasc Intervention
More informationPatients in whom PCI is preferred over CABG _ Aleksander Ernst Clinical Hospital Center Zagreb University of Zagreb School of Medicine Zagreb, CROATIA
3rd Dubrovnik Cardiology Highlights An ESC Update Programme in Cardiology 26.09.-29.09.2013, Hotel Excelsior, Dubrovnik, Croatia Patients in whom PCI is preferred over CABG _ Aleksander Ernst Clinical
More informationThe synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective
SYNTAX STUDY The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective Jacques van Wyk ABSTRACT Panorama Medi-Clinic and Department of Cardiothoracic
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationDeclaration of conflict of interest NONE
Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationSURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS?
SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS? Luigi Martinelli Chief, Dept. of Surgery Istituto Clinico Ligure di Alta Specialità RAPALLO During 1987 2006,
More informationApplication of Appropriate Use Criteria in Clinical Care of CAD. Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University 4/29/2012
Application of Appropriate Use Criteria in Clinical Care of CAD Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University 4/29/2012 Influence of Severity and Location of Stenosis on Cardiac
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationLésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille
Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an
More informationManagement of High-Risk Coronary Artery Disease
Management of High-Risk Coronary Artery Disease Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationChronic Total Occlusions. Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute
Chronic Total Occlusions Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute Financial Disclosures /see -tee-oh / abbr. Med. Chronic Total Occlusion,
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationPCI for Stable Ischemic Heart Disease: What Happened in the Last Week?
PCI for Stable Ischemic Heart Disease: What Happened in the Last Week? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / NewYork Presbyterian Hospital
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationΑγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center
Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center Δεν έχω οικονομική σχέση με φαρμακευτική εταιρία.
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationLEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore Disclosures Advisory Panel, Asian Medical Board Medtronics, Abbott Vascular. Speaker-honoraria,
More informationLeft Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
More informationRADIATION HEART DISEASE: MANAGEMENT STRATEGIES
RADIATION HEART DISEASE: MANAGEMENT STRATEGIES AMMAR CHAUDHARY MBChB, ABIM, FRCPC ASSOCIATE CONSULTANT CARDIOLOGIST KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER - JEDDAH Scope of the Problem ~ 50
More informationIs bypass surgery needed for elderly patients with LMT disease? From the surgical point of view
CCT 2003 (Kobe) Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view Hitoshi Yaku, MD, PhD Department of Cardiovascular Surgery Kyoto Prefectural University of
More informationOn-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery
On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationFRACTIONAL FLOW RESERVE: STANDARD OF CARE
FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationSYNTAX III REVOLUTION Trial Press briefing conference. Prof. Patrick W. Serruys MD, PhD Principal Investigator Imperial College of London
SYNTAX III REVOLUTION Trial Press briefing conference Prof. Patrick W. Serruys MD, PhD Principal Investigator Imperial College of London Title: Coronary Computed Tomography Angiography for Heart Team Decision-making
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationCONTEMPORARY USE OF ARTERIAL GRAFTS DURING CORONARY ARTERY BYPASS SURGERY: PARADIGM SHIFT? OR A LITTLE (MORE) TALK THAT NEEDS A LOT MORE ACTION
CONTEMPORARY USE OF ARTERIAL GRAFTS DURING CORONARY ARTERY BYPASS SURGERY: PARADIGM SHIFT? OR A LITTLE (MORE) TALK THAT NEEDS A LOT MORE ACTION JAMES L ZELLNER MD I have no financial disclosures. 1897
More informationCoronary stenting: the appropriate use of FFR
Coronary stenting: the appropriate use of FFR Morton J. Kern, MD Professor of Medicine Chief of Cardiology LBVA Associate Chief Cardiology University California Irvine Orange, California To treat or not
More information